Sun Pharma

Corporate brand

Sun Pharma is an Indian multinational pharmaceutical company specializing in generic medicines, specialty medicines, branded formulations, and active pharmaceutical ingredients.

Last updated October 26, 2026

AI crawler reads

4requests

1companies

Anthropic4

Profile: 2
Controversies: 2
JSON · MD: 0

First read: Nov 4, 2026
Latest read: Nov 4, 2026

From this site's server log

Overview

Sun Pharma, formally Sun Pharmaceutical Industries Limited, is an Indian multinational pharmaceutical company headquartered in Mumbai. Founded by Dilip Shanghvi in 1983, the company began in Calcutta with five psychiatric products and a two-person marketing team. It subsequently expanded through manufacturing investment, product development, international distribution, and a long series of acquisitions, becoming one of India's largest pharmaceutical companies and a major global supplier of generic and specialty medicines. The company manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients in more than 100 countries. Its business spans conventional generics, branded generics, specialty pharmaceuticals, over-the-counter and consumer-health products, complex formulations, and APIs. Therapeutic areas represented in its portfolio include psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory medicine, oncology, dentistry, and nutritionals. Sun Pharma has a particularly strong position in India and the United States. International markets generate the majority of its revenue, with the US and India together representing the largest portion of its turnover. Its manufacturing network extends across India, the United States, Asia, Africa, Australia, and Europe. The company has used acquisitions to add manufacturing capacity, dermatology expertise, ophthalmology products, sterile injectables, specialty medicines, and regional commercial platforms. A major turning point was Sun Pharma's 2014 agreement to acquire Ranbaxy Laboratories. The transaction, completed subject to regulatory remedies including the divestiture of selected products, substantially increased Sun Pharma's scale and international reach. Other important transactions brought Caraco Pharmaceuticals, Taro Pharmaceuticals, DUSA Pharmaceuticals, URL Pharma's generics business, Pola Pharma, Concert Pharmaceuticals, and additional specialty and regional assets into the broader portfolio. Sun Pharma also maintains an innovation-oriented activity separate from its core commercial operations. In 2007, its research division was demerged and listed as Sun Pharma Advanced Research Company, or SPARC. Sun Pharma's own specialty portfolio has included dermatology, ophthalmology, oncology, and other complex products. Examples include Ilumya, a tildrakizumab product for plaque psoriasis; Odomzo; BromSite; and Cequa for dry-eye disease. The company's positioning combines large-scale, cost-efficient pharmaceutical manufacturing with branded generic distribution and selected specialty medicines. Rather than operating solely as a low-cost generic supplier, Sun Pharma has sought higher-value growth through complex generics, specialty products, differentiated delivery systems, dermatology, ophthalmology, and targeted acquisitions. Its continuing challenges include regulatory compliance, integration of acquired businesses, intellectual-property and market-access issues, and competition from other multinational generic and specialty-pharmaceutical companies.

History

Sun Pharmaceutical Industries was established in 1983 by Dilip Shanghvi in Calcutta, West Bengal. It started with a small psychiatric-medicine portfolio and a two-person marketing operation. The early business model emphasized focused therapeutic products, manufacturing development, and expansion through additional brands and facilities rather than immediate global scale. Sun Pharma became a listed company in 1994. Its public offering was heavily oversubscribed, and the founding family continued to retain a substantial ownership interest. During the 1990s, the company broadened its manufacturing and product base through acquisitions and asset purchases. These included a bulk-drug plant acquired from Knoll Pharmaceuticals in 1996, assets associated with Gujarat Lyka Organics and MJ Pharma, and Tamil Nadu Dadha Pharmaceuticals in 1997. In the same year, Sun Pharma made its first major international move by acquiring Detroit-based Caraco Pharmaceuticals. The company continued adding products and capacity during the late 1990s and early 2000s. It acquired respiratory brands from Natco Pharma in 1998, followed by Melmet Labs, Pradeep Drug Company, and Phlox Pharma. In 2005 it obtained a US formulation plant and a Hungary-based facility from Valeant Pharma and acquired Able Laboratories. Chattem Chemicals was added in 2008. These transactions helped build a manufacturing and commercial platform beyond India. In 2007, Sun Pharma separated its innovative research operations into Sun Pharma Advanced Research Company, which was independently listed as SPARC. The demerger allowed the research organization to pursue new chemical entities and novel drug-delivery systems as a distinct enterprise while Sun Pharma concentrated on its commercial pharmaceutical business. The 2010 acquisition of a controlling interest in Taro Pharmaceuticals was especially important. Taro was a major generic dermatology company with operations in the United States, Canada, and Israel. The deal gave Sun Pharma a stronger specialty position and a broader international platform. In 2012, Sun Pharma added DUSA Pharmaceuticals, a dermatology-device company, and the generics business of URL Pharma. In 2014, it obtained rights from Merck to develop and commercialize tildrakizumab for chronic plaque psoriasis and acquired Pharmalucence to expand US sterile-injectable capabilities. The proposed acquisition of Ranbaxy Laboratories in 2014 was the company's defining scale transaction. Valued at about US$4 billion in the announcement described by reference sources, it combined two of India's largest pharmaceutical businesses and was intended to create the world's fifth-largest specialty-generics company by sales. The Competition Commission of India approved the transaction subject to remedies, including the divestiture of seven products, to address competition concerns. The integration increased Sun Pharma's international footprint but also added operational complexity and regulatory responsibilities. Sun Pharma pursued further geographic and therapeutic expansion after the Ranbaxy transaction. In 2015 it agreed to acquire GlaxoSmithKline's Australian opiates business. In 2016 it bought prescription brands from Novartis in Japan, acquired Ocular Technologies to reinforce ophthalmology, and purchased Biosintez to increase its Russian presence. The company launched BromSite, its first branded ophthalmic product in the United States, in 2016, followed by Odomzo in 2017 and Ilumya in 2018. In 2019 it acquired Japanese dermatology company Pola Pharma, entered the Greater China market through a partnership with China Medical System Holdings, and launched Cequa in the United States for dry-eye disease. More recent expansion has emphasized specialty medicines, biotechnology, animal health, and targeted oncology. In 2023 Sun Pharma acquired Concert Pharmaceuticals and a 60% interest in Vivaldis Animal Health and Foods. It also entered a licensing arrangement with Pharmazz. In 2024 it announced a definitive merger agreement to acquire the remaining stake in Taro Pharmaceuticals. In 2025 it announced the acquisition of Checkpoint Therapeutics, a US company focused on immunotherapy and targeted oncology treatments. Today, Sun Pharma operates as a diversified multinational pharmaceutical company with manufacturing across India and several overseas regions. Its portfolio covers APIs, generic and branded-generic medicines, specialty products, and a wide range of therapeutic fields. Its strategic identity is built on combining Indian manufacturing scale with international commercialization, acquired brands, complex products, and selected proprietary or licensed specialty therapies.

2023
Concert Pharmaceuticals and Vivaldis investments expanded the portfolio
[1]Sun Pharmaen.wikipedia.org
Sun Pharma added biotechnology and animal-health interests through acquisitions and a majority investment.
2018
Ilumya was launched
[1]Sun Pharmaen.wikipedia.org
Sun Pharma launched its tildrakizumab specialty product for moderate-to-severe plaque psoriasis.
2014
Ranbaxy acquisition was announced
[1]Sun Pharmaen.wikipedia.org
The transaction significantly increased Sun Pharma's scale and global reach, subject to competition remedies.
2010
Taro Pharmaceuticals became a controlled subsidiary
[1]Sun Pharmaen.wikipedia.org
Sun Pharma acquired a controlling stake in the international generic-dermatology company.
2007
Innovative research was separated into SPARC
[1]Sun Pharmaen.wikipedia.org
Sun Pharma demerged its innovative research arm and listed Sun Pharma Advanced Research Company separately.
1997
Sun Pharma made its first major international acquisition
[1]Sun Pharmaen.wikipedia.org
The acquisition of Caraco Pharmaceuticals in Detroit marked an important step into the international market.
1994
The company became publicly listed
[1]Sun Pharmaen.wikipedia.org
Sun Pharma listed on Indian stock exchanges following a highly oversubscribed public issue.
1983
Sun Pharma was founded
[1]Sun Pharmaen.wikipedia.org
Dilip Shanghvi established the company in Calcutta with five psychiatric products and a two-person marketing team.

Products and positioning

A global Indian pharmaceutical company combining high-volume generic and branded-generic manufacturing with specialty medicines, complex formulations, APIs, and focused therapeutic franchises, especially dermatology and ophthalmology.

Specialty dermatology medicine · 2018
Ilumya
Ilumya is Sun Pharma's branded tildrakizumab-asmn product for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It represents the company's strategy of developing and commercializing differentiated specialty medicines alongside its generic portfolio.
Ophthalmology · 2019
Cequa
Cequa is a branded ophthalmic product launched in the United States for dry-eye disease. Its introduction strengthened Sun Pharma's branded ophthalmology platform and complemented the company's broader interest in complex and specialty eye-care products.
Ophthalmology · 2016
BromSite
BromSite was Sun Pharma's first branded ophthalmic product in the United States. Its launch demonstrated the company's effort to build proprietary or differentiated branded products rather than relying exclusively on commodity generics.
Oncology and specialty medicine · 2017
Odomzo
Odomzo is a specialty product associated with Sun Pharma's expansion into branded specialty medicines. Its launch formed part of the company's effort to build higher-value products in oncology and other focused therapeutic areas.
Prescription pharmaceuticals
Generic and branded-generic portfolio
Sun Pharma sells a broad portfolio of generic and branded-generic medicines across psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory medicine, oncology, dentistry, and nutritionals. The portfolio is marketed in India and international markets through local subsidiaries, partners, and acquired businesses.
Pharmaceutical ingredients
Active pharmaceutical ingredients
Sun Pharma manufactures and sells APIs used in pharmaceutical production. Reference materials identify baricitinib, brivaracetam, and dapagliflozin among its API-related products. API operations complement the company's finished-dose formulation business and support its vertically integrated manufacturing model.

Controversies

2020
DUSA reaches DOJ settlement over drug promotion allegations
DUSA Pharmaceuticals, a wholly owned subsidiary of Sun Pharmaceutical Industries, reached a civil settlement with the U.S. Department of Justice and agreed to pay $20.75 million to resolve allegations related to the promotion of LEVULAN KERASTICK and BLU-U. The settlement does not constitute an admission of liability or wrongdoing.
Source
2020
Sun Pharma recalls a lot of Riomet ER
Sun Pharmaceutical Industries Inc stated that it was voluntarily recalling one lot of Riomet ER oral suspension in the United States because NDMA levels exceeded the allowable acceptable daily intake limit. The company said it had received no reports of adverse events related to the recall. The recall was described as voluntary and limited to a single lot of the oral suspension product.
Source
2020
Sun Pharma recalls RIOMET ER bottles in the US over NDMA impurity
Sun Pharmaceutical Industries, through its US-based subsidiary, recalled 747 bottles of RIOMET ER in the US after NDMA impurity was detected in the finished drug product. The US regulator classified it as a Class II recall.
Source

2024
Proposed acquisition of the remaining Taro stakeM&A
Background
Sun Pharma already controlled Taro and sought to simplify ownership by acquiring the shares it did not hold.
Action taken
The parties entered a definitive merger agreement for Sun Pharma to acquire the remaining Taro interest.
Aftermath
The proposal was intended to consolidate Taro's dermatology and generic-pharmaceutical operations more directly within Sun Pharma.
Announced consideration. US$347.73 million (2024 announcement)
Source
2018
Launch Ilumya for plaque psoriasisProduct launch
Background
Sun Pharma aimed to expand its specialty-medicine business beyond traditional generic pharmaceuticals.
Action taken
The company launched Ilumya, its tildrakizumab-asmn product for moderate-to-severe chronic plaque psoriasis.
Aftermath
The launch established a more visible specialty-dermatology presence in the company's branded portfolio.
Source
2014
Acquire Ranbaxy LaboratoriesM&A
Background
Sun Pharma sought to increase its scale, geographic reach, manufacturing base, and specialty-generics capabilities through a combination with Ranbaxy.
Action taken
The company announced the acquisition and proceeded through regulatory review. Indian competition authorities required the divestiture of seven products as a condition of approval.
Aftermath
The transaction created a substantially larger global pharmaceutical group, while requiring integration of Ranbaxy's operations and product portfolio.
Announced transaction value. Approximately US$4 billion (2014 announcement)
Source

Recent events

2022.03.08
Sun Pharma subsidiary completes acquisition of Galderma subsidiaries[6]Sun Pharma子公司完成收购Galderma旗下子公司indiainfoline.com
Sun Pharmaceutical Industries Limited subsidiary Taro Pharmaceuticals USA Inc completed the acquisition of Galderma subsidiaries, including entities incorporated in Delaware, Japan and Canada. The acquired subsidiaries sold products under the Proactiv, Restorative Elements and In Defense of Skin brands; the transaction price was $99.279 million.
2021.09.01
Reported2021.09.01
Sun Pharma Japan sells Kayaku Co. Ltd.[7]Sun Pharma Japan 出售 Kayaku Co. Ltd.equitybulls.com
Sun Pharma Japan sold its entire shareholding in Kayaku Co. Ltd. to Shinshin Pharmaceutical Co., Ltd. for JPY 353,983,400; Kayaku ceased to be a Sun Pharmaceutical Industries subsidiary.
2021.05.28
Reported2021.05.28
Sun Pharma acquires Oxra trademark and manufacturing rights in India[8]Sun Pharma 获得 Oxra 等商标及相关制造权利equitybulls.com
Sun Pharma acquired the Indian rights to the Oxra, Oxramet and Oxraduo trademarks from AstraZeneca AB, and took a patent license from AstraZeneca AB to manufacture and commercialize dapagliflozin and its combination with metformin in India.
2021.05.28
Reported2021.05.28
Sun Pharma acquires Indian trademark rights for dapagliflozin products[9]太阳制药获得达格列净产品在印度的商标权business-standard.com
Sun Pharma acquired the Indian rights to the Oxra, Oxramet and Oxraduo trademarks from AstraZeneca AB, with effect from 28 May 2021.
2021.05.28
Reported2021.05.28
Sun Pharma and AstraZeneca India discontinue distribution agreement[8]Sun Pharma 获得 Oxra 等商标及相关制造权利equitybulls.com
Sun Pharma and AstraZeneca India discontinued their 2016 distribution agreement, effective May 28, 2021.
2021.05.28
Reported2021.05.28
AstraZeneca India and Sun Pharma enter transition supply agreement[8]Sun Pharma 获得 Oxra 等商标及相关制造权利equitybulls.com
AstraZeneca India and Sun Pharma entered into a transition supply agreement effective May 28, 2021. AstraZeneca India will supply dapagliflozin and its combination with metformin to Sun Pharma until a mutually agreed point, after which those supplies will cease.
2021.05.28
Reported2021.05.28
AstraZeneca AB licenses dapagliflozin rights to Sun Pharma in India[9]太阳制药获得达格列净产品在印度的商标权business-standard.com
AstraZeneca AB granted Sun Pharma a patent license to manufacture and commercialize dapagliflozin and its combination with metformin in India, effective 28 May 2021.
2021.05.21
Reported2021.05.21
Sun Pharma appoints two additional independent directors[10]Sun Pharma任命两名额外独立董事economictimes.indiatimes.com
Sun Pharma appointed Pawan Goenka and Rama Bijapurkar as additional independent directors, effective May 21, 2021.
2021.04.05
Reported2021.04.06
DigiHealth completes acquisition of 91.8% stake in Pharmarack Technologies[11]DigiHealth完成收购Pharmarack Technologies 91.8%股权business-standard.com
DigiHealth Technologies LLP completed the acquisition of a 91.8% stake in Pharmarack Technologies on April 5, 2021. Sun Pharmaceutical Industries announced the completion; DigiHealth is identified as an entity of an investee of the company's Indian wholly owned subsidiary.
2020.09.24
Reported2020.09.24
Sun Pharma recalls a lot of Riomet ER[3]Sun Pharma recalls a lot of Riomet ERbusiness-standard.com
Sun Pharmaceutical Industries Inc said it was voluntarily recalling one lot of Riomet ER oral suspension in the US because NDMA levels exceeded the allowable acceptable daily intake limit. The company said it had received no reports of adverse events related to the recall.

Sources26 sources

Cite this profile: Cite the canonical profile. /brand-wiki/sun-pharma · Editorial policy · How profiles are compiled